LabGenomics USA LLC Acquires QDx Pathology
September 5, 2023
LabGenomics USA LLC, a subsidiary of South Korea–based LabGenomics Co., Ltd., has acquired QDx Pathology, a U.S. clinical and molecular pathology laboratory. The deal, signed in August 2023, is intended to accelerate LabGenomics' entry and expansion into the North American diagnostics market by combining QDx's lab services with LabGenomics' NGS-based molecular diagnostics capabilities.
- Buyers
- LabGenomics USA LLC, LabGenomics Co., Ltd.
- Targets
- QDx Pathology Services
- Industry
- Healthcare Services
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Labcorp Acquires Personal Genome Diagnostics (PGDx)
February 21, 2022
Healthcare Services
Labcorp completed its acquisition of Personal Genome Diagnostics (PGDx), a cancer genomics company that develops liquid biopsy and tissue-based NGS products. Labcorp paid $450 million in cash at closing plus up to $125 million in performance-based milestones to expand its oncology genomics and liquid biopsy capabilities and accelerate access to precision diagnostics for clinical care and trials.
-
NeoGenomics Acquires Pathline
April 7, 2025
Healthcare Services
NeoGenomics, Inc. (NASDAQ: NEO) has completed its acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified pathology laboratory headquartered in Ramsey, New Jersey. The deal strengthens NeoGenomics' commercial presence in the Northeast United States and expands its molecular and hematology-oncology testing capabilities and access to its oncology test menu.
-
LabGenomics USA Acquires Integrated Molecular Diagnostics (IMD) CLIA Labs
October 25, 2024
Healthcare Services
LabGenomics USA acquired Integrated Molecular Diagnostics (IMD) CLIA labs, expanding its U.S. footprint to four CLIA-certified laboratories and strengthening its molecular and oncology diagnostic capabilities. The deal broadens LabGenomics' geographic reach across the U.S. coasts and positions the company to launch new laboratory-developed tests (LDTs) and expand reimbursable services.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
SourceBio International plc Acquires LDPath Limited
March 29, 2022
Healthcare Services
SourceBio International plc has completed a strategic acquisition of LDPath Limited, a London-based digital pathology testing provider. The deal expands SourceBio's digital and AI-enabled pathology capabilities and creates a larger private provider of cellular and digital pathology services for the U.K. healthcare market.
-
EmeritusDX Acquires Freedom Pathology Partners
June 13, 2022
Healthcare Services
EmeritusDX, a cancer diagnostics and information company, has acquired Freedom Pathology Partners, a CAP- and CLIA-accredited laboratory based in Conshohocken, Pennsylvania. The acquisition expands EmeritusDX’s national presence and test menu—adding anatomic pathology, FISH, and molecular testing capabilities and strengthening relationships in dermatology, gastroenterology, and urology markets.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.